16 July 2020: OIA response: Special Authority data for Risperdal Consta, Zyprexa Relprevv, Invega Sustenna
16 July 2020
Dear [name and contact details withheld]
REQUEST FOR INFORMATION
Thank you for your email of 15 June 2020, in which you have requested the following information:
- New special authorities for Risperdal Consta (risperidone depot injection), Zyprexa Relprevv (olanzapine depot injection) and Invega Sustenna (paliperidone depot injection) during the period Jan 2009 to 31 May 2020.
- Renewal special authorities for Risperdal Consta, Zyprexa Relprevv and Invega Sustenna during the period Jan 2009 to 31 May 2020
- Demographic information on gender, age, ethnicity relating to each molecule initiation
- Length of time on treatment (or proxy) (see below for further information)
The data you have requested is attached. Please note that PHARMAC can only provide Special Authority data for Risperdal Consta, Zyprexa Relprevv and Invega Sustenna up to the end of December 2019.
Your request for this data was considered under the Official Information Act (OIA). PHARMAC approaches its requests for information under the OIA on the basis that, once released, the information becomes publicly available - in other words once we release the information to you it becomes available to any other party in that exact form (whether by you distributing it to others or by virtue of us receiving the same request from a different third party). To protect the privacy of natural persons (section 9(2)(a)), we have used the symbol <10 to indicate where data reflects less than 10 individuals.
As required under the OIA, we also considered whether, in the circumstances, the withholding of this personal information was outweighed by other considerations which render it desirable, in the public interest, to make this information available. In this case we did not consider that the public interest outweighed the reasons for withholding the information.
Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.
We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.
Director, Engagement and Implementation